Not all neurological Lyme disease looks the same — here’s what spinal fluid reveals

  • 2026 September 17.
  • 1281 megtekintés

A Slovenian study analyzing data from 405 patients offers a detailed picture of how the three main clinical forms of Lyme neuroborreliosis affect the cerebrospinal fluid (CSF) differently. The findings help explain why the course and severity of the disease can vary so much from one patient to another.

Research conducted by: Katarina Ogrinc, Petra Bogovič, Andrej Kastrin, Eva Ružić-Sabljić, and Franc Strle

Three faces, one disease

Lyme neuroborreliosis (LNB), the neurological form of Lyme disease, typically presents in Europe as one of three clinical pictures: meningoradiculoneuritis (also known as Bannwarth syndrome), marked by severe nerve-root pain, sometimes accompanied by cranial nerve involvement such as facial palsy; cranial neuritis, where a cranial nerve problem (most often one-sided facial palsy) occurs on its own, without radicular pain; and meningitis associated with erythema migrans, the characteristic Lyme skin rash (EM-meningitis).

Although the clinical features of these three forms are well known, it had not been systematically mapped how much they differ in cerebrospinal fluid (CSF) inflammation — or how those differences evolve depending on how long symptoms have been present.

The study

The Slovenian research team retrospectively analyzed data from 405 patients with confirmed early LNB, treated at a single center between 2005 and 2025. Thirteen routine CSF parameters — including cell count, protein and albumin levels, and IgM and IgG antibody levels — were compared across the three clinical forms, and the researchers also examined how these values changed depending on how long neurological symptoms had been present.

What the numbers show

Of the 405 patients, 274 (68%) had Bannwarth syndrome, 82 (20%) cranial neuritis, and 49 (12%) EM-meningitis. Patients with Bannwarth syndrome were significantly older (median age 61, versus 47 and 48 in the other two groups) and had had symptoms for considerably longer by the time of CSF testing (median 24 days, versus 10 days in each of the other two forms).

The severity of CSF abnormalities tracked closely with the clinical form: the more pronounced the nerve-root involvement, the stronger the inflammation measured in the CSF. The white blood cell count in the spinal fluid — one of the most basic markers of inflammation — had a median of 157 cells/µL in Bannwarth syndrome, 66 cells/µL in cranial neuritis, and just 37 cells/µL in EM-meningitis (p<0.001 for every paired comparison favoring Bannwarth syndrome). Protein levels and IgM/IgG antibody levels in the CSF followed the same pattern — highest in Bannwarth syndrome, lowest in EM-meningitis.

Borrelia-specific antibodies followed a similar gradient: serum borrelial IgG was positive in 93% of Bannwarth syndrome patients, 79% of cranial neuritis patients, and 61% of EM-meningitis patients. CSF culture — direct detection of the bacterium itself — was positive in only about 10% of samples overall, with no significant difference between the three forms.

Breaking antibody positivity down by clinical form (Figure 3) reveals an interesting, form-specific asymmetry between serum and CSF. For IgM, CSF positivity exceeded serum positivity in Bannwarth syndrome (73.4% vs. 51.1%) and in cranial neuritis (58.5% vs. 46.3%) — meaning intrathecal IgM production was often present even when serum testing alone was negative or inconclusive. In EM-meningitis, however, the pattern reversed: serum IgM was positive more often than CSF IgM (53.1% vs. 40.8%), in line with this form’s generally milder intrathecal immune response. IgG followed a related pattern: positivity was high and fairly similar between serum and CSF in Bannwarth syndrome (93.1% vs. 90.9%) and cranial neuritis (79.3% vs. 80.5%), but in EM-meningitis, serum IgG was again notably more often positive than CSF IgG (61.2% vs. 49.0%). Together, these figures help explain why relying on serum serology alone can miss cases of neuroborreliosis — particularly Bannwarth syndrome with early, IgM-predominant disease — and why CSF testing remains central to a confident diagnosis, even as EM-meningitis shows that the intrathecal antibody response itself can vary substantially by clinical form.

Interestingly, CSF values also followed a distinct pattern over time: cell count, protein, and albumin levels rose steadily during the first 4 weeks after symptom onset and then plateaued, while IgM and IgG antibody levels peaked somewhat later, around week 6. The longer symptoms had been present before CSF testing, the higher the lymphocyte proportion and antibody levels tended to be — suggesting that a CSF result is not a single snapshot, but a point along an evolving process.

Figure 2: Median white blood cell count in cerebrospinal fluid according to the three clinical forms. Protein and antibody levels showed a similar pattern.

Figure 3: Serum versus cerebrospinal fluid antibody positivity (IgM and IgG), broken down by clinical form.

What does this mean in practice?

The study’s key message is that early European Lyme neuroborreliosis is not a single, uniform disease but a clinical spectrum whose forms differ quantitatively in the degree of neurological inflammation and blood-brain barrier disruption: Bannwarth syndrome shows the most pronounced CSF changes, EM-meningitis the mildest.

Because CSF values change substantially over the first weeks to months of illness, the timing of the lumbar puncture (spinal tap) relative to symptom onset matters when interpreting results — which further underscores the value of early diagnostic evaluation. It’s worth stressing, though, that there is considerable overlap between individual patients across the three forms, meaning a CSF result alone cannot reliably pinpoint which clinical form a given patient has — rather, it helps explain why the disease’s course can look so different from person to person.

From the perspective of day-to-day diagnosis, it is noteworthy that the laboratory diagnostic criterion for Lyme neuroborreliosis – the simultaneous positivity of serum and cerebrospinal fluid samples, which is a mandatory requirement in many countries – does not even reach a rate of 50 per cent in certain groups. It is therefore unsuitable for either confirming LNB or definitively ruling it out.



SOURCE AND FURTHER READING

Ogrinc K, Bogovič P, Kastrin A, Ružić-Sabljić E, Strle F. Cerebrospinal fluid profiles across clinical manifestations of early European Lyme neuroborreliosis. Open Forum Infectious Diseases, 2026. doi:10.1093/ofid/ofag555 — © The author(s), 2026. Published by Oxford University Press on behalf of the Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA). Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International (CC BY-NC-ND 4.0) licence.

This article is a lay-person’s summary, written in more accessible language, based on the peer-reviewed scientific paper cited above. It is not a substitute for medical advice; please consult your GP regarding any questions relating to treatment or diagnosis.

(C) Lyme Borreliosis Foundation